Author/Authors :
Safaei, Akbar Department of Hematopathology - Molecular Pathology and Cytogenetics - Shiraz University of Medical Sciences, Shiraz, Iran , Monabati, Ahmad Department of Hematopathology - Molecular Pathology and Cytogenetics - Shiraz University of Medical Sciences, Shiraz, Iran , Mokhtari, Maral Department of Hematopathology - Molecular Pathology and Cytogenetics - Shiraz University of Medical Sciences, Shiraz, Iran , Montazer, Mehdi Department of Hematopathology - Molecular Pathology and Cytogenetics - Shiraz University of Medical Sciences, Shiraz, Iran
Abstract :
The emerging era of personalized medicine makes it increasingly important to
consider intratumoral heterogeneity, which has been found in some breast cancer
cases. However, its identification criteria, form of reporting, and subsequent effects on
the clinical course of this disease remain controversial and not fully defined. Here, we
report and discuss a case of breast invasive ductal adenocarcinoma with substantial
intratumoral heterogeneity, discrepancy between Her2/neu immunostaining and in
situ hybridization, and disparity between estrogen receptor status before and after
neoadjuvant therapy.
Keywords :
Personalized medicine , Genetic heterogeneity , ErbB-2 , Estrogen receptor , Breast
